These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 23420876)
1. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. Matin RN; Chikh A; Chong SL; Mesher D; Graf M; Sanza' P; Senatore V; Scatolini M; Moretti F; Leigh IM; Proby CM; Costanzo A; Chiorino G; Cerio R; Harwood CA; Bergamaschi D J Exp Med; 2013 Mar; 210(3):581-603. PubMed ID: 23420876 [TBL] [Abstract][Full Text] [Related]
2. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316 [TBL] [Abstract][Full Text] [Related]
3. Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal. DeCoste RC; Carter MD; Pasternak S; Fleming KE; Gaston D; Legge A; Ly TY; Walsh NM Hum Pathol; 2021 Nov; 117():31-41. PubMed ID: 34391748 [TBL] [Abstract][Full Text] [Related]
4. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Petitjean A; Ruptier C; Tribollet V; Hautefeuille A; Chardon F; Cavard C; Puisieux A; Hainaut P; Caron de Fromentel C Carcinogenesis; 2008 Feb; 29(2):273-81. PubMed ID: 18048390 [TBL] [Abstract][Full Text] [Related]
5. One, two, three--p53, p63, p73 and chemosensitivity. Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142 [TBL] [Abstract][Full Text] [Related]
6. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. Dar AA; Majid S; Rittsteuer C; de Semir D; Bezrookove V; Tong S; Nosrati M; Sagebiel R; Miller JR; Kashani-Sabet M J Natl Cancer Inst; 2013 Mar; 105(6):433-42. PubMed ID: 23365201 [TBL] [Abstract][Full Text] [Related]
7. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Liu Q; Mier JW; Panka DJ Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745 [TBL] [Abstract][Full Text] [Related]
8. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Petitjean A; Cavard C; Shi H; Tribollet V; Hainaut P; Caron de Fromentel C Oncogene; 2005 Jan; 24(3):512-9. PubMed ID: 15543231 [TBL] [Abstract][Full Text] [Related]
10. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer. Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835 [TBL] [Abstract][Full Text] [Related]
11. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921 [TBL] [Abstract][Full Text] [Related]
12. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. Ji Z; Njauw CN; Taylor M; Neel V; Flaherty KT; Tsao H J Invest Dermatol; 2012 Feb; 132(2):356-64. PubMed ID: 21993556 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Seitz SJ; Schleithoff ES; Koch A; Schuster A; Teufel A; Staib F; Stremmel W; Melino G; Krammer PH; Schilling T; Müller M Int J Cancer; 2010 May; 126(9):2049-66. PubMed ID: 19711344 [TBL] [Abstract][Full Text] [Related]
14. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291 [TBL] [Abstract][Full Text] [Related]
15. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872 [TBL] [Abstract][Full Text] [Related]
16. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545 [TBL] [Abstract][Full Text] [Related]
17. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570 [TBL] [Abstract][Full Text] [Related]
18. TP53 family members and human cancers. Bénard J; Douc-Rasy S; Ahomadegbe JC Hum Mutat; 2003 Mar; 21(3):182-91. PubMed ID: 12619104 [TBL] [Abstract][Full Text] [Related]
19. ZNF23 Suppresses Cutaneous Melanoma Cell Malignancy via Mitochondria-Dependent Pathway. Zhang X; Ding C; Tian H; Dong X; Meng X; Zhu W; Liu B; Wang L; Huang M; Li C Cell Physiol Biochem; 2017; 43(1):147-157. PubMed ID: 28848158 [TBL] [Abstract][Full Text] [Related]